البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
MOGAMULIZUMAB
KYOWA KIRIN, INC.
L01FX09
MOGAMULIZUMAB
4MG
SOLUTION
MOGAMULIZUMAB 4MG
INTRAVENOUS
100
Schedule D
Active ingredient group (AIG) number: 0163781001; AHFS:
APPROVED
2022-06-02
_POTELIGEO (mogamulizumab for injection) _ _Page 1 of 25_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr POTELIGEO ® Mogamulizumab for injection 20 mg/5 mL single-use vial Intravenous Infusion, 4 mg/mL Antineoplastic ATC Code: L01FX09 Kyowa Kirin, Inc. 135 Route 202/206, Suite 6 Bedminster, NJ 07921 USA www.kyowakirin.ca DISTRIBUTOR: Innomar Strategies 3470 Superior Court Oakville, ON L6L 0C4 http://www.innomar-strategies.com Date of Initial Authorization: June 2, 2022 Date of Revision: June 20, 2022 Submission Control Number: 251277 _ _ _POTELIGEO (mogamulizumab for injection) _ _Page 2 of 25_ RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS ................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics.............................................................................................................4 2 CONTRAINDICATIONS ...................................................................................................4 4 DOSAGE AND ADMINISTRATION...................................................................................4 4.1 Dosing Considerations .........................................................................................4 4.2 Recommended Dose and Dosage Adjustment.......................................................4 4.3 Reconstitution ........................................................................... اقرأ الوثيقة كاملة